Pharmaceuticals News and Research

RSS

Neuland Laboratories announces financial results for third quarter of fiscal year 2014

Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2014, ended December 31, 2013.

5 Feb 2014

Viewpoints: Drop in abortion rates may have something to do with better contraception; GOP health law alternative 'designed to fail'

A new study released on Monday finds that the abortion rate among American women declined to its lowest level in more than three decades in 2011. ... Notably, though, the decline in abortions from 2008 to 2011 was mirrored by a decline in pregnancy rates that the researchers say may reflect stricter adherence to birth control methods during recession, and the growing use, especially among younger women, of reliable long-term contraceptives, like the intrauterine device, or IUD.

5 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

95% of adults die annually from vaccine preventable diseases

While adults make up 95 percent of those who die annually from vaccine preventable diseases, a new study from the University of Colorado School of Medicine shows their vaccination rates remain stubbornly low, representing a growing public health concern.

5 Feb 2014

New drug treatment effective against chronic pain caused by nerve damage post shingles

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

5 Feb 2014

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.

4 Feb 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia.

4 Feb 2014

Study focuses on development and spread of Alzheimer's disease throughout the brain

The development of Alzheimer's disease and the way it spreads throughout the brain will be the focus of a pioneering study conducted at Aston University (UK).

4 Feb 2014

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

3 Feb 2014

Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Antibiotic resistance is a consequence of antibiotic use. Bacteria adapt to the threat of antibiotics using mechanisms to overcome the drug. These bacteria, which we call resistant bacteria, then survive.

3 Feb 2014

Ferrer executes two agreements to support clinical studies of Lorediplon in insomnia patients

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has executed two agreements; with Ildong Pharmaceuticals Co Ltd, Korea and Ergomed Clinical Research Ltd, UK to support further clinical studies of Lorediplon in patients with insomnia.

3 Feb 2014

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

3 Feb 2014

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

31 Jan 2014

CICC signs agreement with BEUB to distribute nutriceutical products

On January 27, 2014, China Internet Cafe Holdings Group Inc. ("CICC" or the "Company") (OTCQB: CICC), a leading chain of Internet cafes in the People's Republic of China, announced that it signed a distribution agreement with Beijing Eastern Union Biopharmaceuticals, Ltd.

31 Jan 2014

Trevena prices initial public offering of common stock

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.

31 Jan 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

The first clinical study of a low-cost neonatal breathing system created by Rice University bioengineering students demonstrated that the device increased the survival rate of newborns with severe respiratory illness from 44 percent to 71 percent.

31 Jan 2014

Pharmaceuticals News and Research

Neuland Laboratories announces financial results for third quarter of fiscal year 2014

Viewpoints: Drop in abortion rates may have something to do with better contraception; GOP health law alternative 'designed to fail'

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

95% of adults die annually from vaccine preventable diseases

New drug treatment effective against chronic pain caused by nerve damage post shingles

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Study focuses on development and spread of Alzheimer's disease throughout the brain

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Ferrer executes two agreements to support clinical studies of Lorediplon in insomnia patients

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

CICC signs agreement with BEUB to distribute nutriceutical products

Trevena prices initial public offering of common stock

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence